Dolutegravir (DTG) and lamivudine (3TC) clinical trials

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

This study looks at a two-drug treatment (Dolutegravir and Lamivudine) for children and young people with HIV, aged 2 to 15. It aims to see if it's as safe and effective as their current three-drug therapy.